Claims
- 1. A method for reducing copper levels in a patient in need thereof comprising administering to said patient a therapeutically effective amount of at least one amine polymer, wherein the amine polymer is substantially water-insoluble or non-absorbent in the gastrointestinal tract.
- 2. The method of claim 1 wherein the amine polymer is aliphatic.
- 3. The method of claim 1 wherein the polymer is characterized by a repeat unit having a formula selected from the group consisting of:
- 4. The method of claim 3 wherein said polymer is cross-linked by means of a multifunctional cross-linking agent.
- 5. The method of claim 3 wherein at least one of R, R1, R2, and R3 in each formula is hydrogen.
- 6. The method of claim 4 wherein the multifunctional cross-linking agent is present in an amount from about 0.5-25% by weight, based upon the combined weight of monomer and cross-linking agent.
- 7. The method of claim 4 wherein the multifunctional cross-linking agent is present in an amount from about 2.5-20% by weight, based upon the combined weight of monomer and cross-linking agent.
- 8. The method of claim 4 wherein said cross-linking agent comprises epichlorohydrin.
- 9. The method of claim 4 wherein the polymer is a homopolymer.
- 10. The method of claim 4 wherein the polymer is a polyallylamine.
- 11. The method of claim 4 wherein the polymer is a polydiallylamine.
- 12. The method of claim 4 wherein the polymer is a polyethyleneimine.
- 13. The method of claim 8 wherein the polymer is a polyvinylamine.
- 14. The method of claim 4 wherein the polymer is selected from the group consisting of polybutenylamine, polylysine, polyarginine, and poly(aminopropylacrylamide), and mixtures thereof.
- 15. The method of claim 1 wherein the amine polymer is administered with one or more meals.
- 16. The method of claim 1 wherein the amine polymer is administered to the gastrointestinal tract in a dosage comprising between about 1 μg/kg/day and about 1 g/kg/day.
- 17. A method for treating Wilson's disease in a patient in need thereof comprising administering to said patient a therapeutically effective amount of at least one amine polymer, wherein the amine polymer is substantially water-insoluble or non-absorbent in the gastrointestinal tract.
- 18. The method of claim 17 wherein the amine polymer is aliphatic.
- 19. The method of claim 17 wherein the polymer is characterized by a repeat unit having a formula selected from the group consisting of:
- 20. The method of claim 19 wherein said polymer is cross-linked by means of a multifunctional cross-linking agent.
- 21. The method of claim 19 wherein at least one of R, R1, R2, and R3 in each formula is hydrogen.
- 22. The method of claim 20 wherein the multifunctional cross-linking agent is present in an amount from about 0.5-25% by weight, based upon the combined weight of monomer and cross-linking agent.
- 23. The method of claim 20 wherein the multifunctional cross-linking agent is present in an amount from about 2.5-20% by weight, based upon the combined weight of monomer and cross-linking agent.
- 24. The method of claim 20 wherein said cross-linking agent comprises epichlorohydrin.
- 25. The method of claim 20 wherein the polymer is a homopolymer.
- 26. The method of claim 20 wherein the polymer is a polyallylamine.
- 27. The method of claim 20 wherein the polymer is a polydiallylamine.
- 28. The method of claim 20 wherein the polymer is a polyethyleneimine.
- 29. The method of claim 24 wherein the polymer is a polyvinylamine.
- 30. The method of claim 20 wherein the polymer is selected from the group consisting of polybutenylamine, polylysine, polyarginine, and poly(aminopropylacrylamide), and mixtures thereof.
- 31. The method of claim 17 wherein the amine polymer is administered with one or more meals.
- 32. The method of claim 17 wherein the amine polymer is administered to the gastrointestinal tract in a dosage comprising between about 1 μg/kg/day and about 1 g/kg/day.
- 33. A method for reducing copper levels in a patient in need thereof comprising administering to said patient a therapeutically effective amount of sevelamer hydrogen chloride.
- 34. A method for reducing copper levels in a patient in need thereof comprising administering to said patient a therapeutically effective amount of colesevelam.
- 35. Use of a therapeutically effective amount of at least one amine polymer for the manufacture of a medicament for the purpose of reducing copper levels in an individual in need thereof, wherein the amine polymer is substantially water-insoluble or non-absorbent in the intestinal tract.
- 36. Use of a therapeutically effective amount of at least one polymer that binds copper for the manufacture of a medicament for treating Wilson's disease.
RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 60/305,592, filed on Jul. 13, 2001, and U.S. Provisional Application No. 60/284,445, filed on Apr. 18, 2001.
[0002] The entire teachings of the above applications are incorporated herein by reference.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60305592 |
Jul 2001 |
US |
|
60284445 |
Apr 2001 |
US |